Rheumatology Information Service Europe
Prevalence and Impact of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a progressive, debilitating disease that inflicts serious physical, emotional and economic consequences.1

RA is a chronic, heterogeneous disease of uncertain aetiology.2

RA affects more than 2.9 million Europeans.3
The clinical course of RA fluctuates and prognosis is unpredictable.4
70% of patients with recent onset of RA show evidence of radiographic changes within 3 years.5
50% of RA patients are work-disabled within 10 years of disease onset.6


In the long term, the major outcomes of RA include joint deformity, joint malalignment, the need for joint replacement surgery, functional disability, work disability and often premature death.7 Thus, RA not only represents a significant burden for the patient, it is also associated with significant direct treatment costs, high indirect costs (including loss of productivity) and intangible costs that may result from factors such as pain and fatigue.7 Despite the high direct costs, the indirect costs are considered to be of greater significance due to the extensive morbidity associated with disease.8

RA is associated with significant costs


Downloads
Prevalence and impact of Rheumatoid Arthritis.ppt
Prevalence and impact of RA.ppt
Find out more about the importance of early RA treatment in limiting the adverse consequences of the disease.
» View document
» Download document

References
© 2008 Biovitrum AB (publ). All rights reserved.
This is a European website containing information about Kineret® (anakinra) and is intended for healthcare professionals within the European Union. The information on this site is not country-specific and may contain product-related information that is outside the approved product data sheet in the country in which you are located.
» Privacy Policy     » Terms of Use     » Contact Us